TY - JOUR
T1 - Effectiveness of different dosing regimens of risperidone and olanzapine in schizophrenia
AU - Takeuchi, Hiroyoshi
AU - Fervaha, Gagan
AU - Lee, Jimmy
AU - Agid, Ofer
AU - Remington, Gary
N1 - Funding Information:
Data used in the preparation of this article were obtained from the limited access datasets (Version 1) distributed from the NIH-supported “Clinical Antipsychotic Trials of Intervention Effectiveness in Schizophrenia” (CATIE-Sz). This is a multisite, clinical trial of persons with schizophrenia comparing the effectiveness of randomly assigned medication treatment. The study was supported by NIMH Contract # N01MH90001 to the University of North Carolina at Chapel Hill . The ClinicalTrials.gov identifier is NCT00014001 . This manuscript reflects the views of the authors and may not reflect the opinions or views of the CATIE-Sz Study Investigators or the NIH.
Funding Information:
Dr. Takeuchi is supported by the Canadian Institutes of Health Research (CIHR) under its Fellowship. This funding source had no further role in study design, statistical analysis or interpretation of findings; in writing of the manuscript; or in the decision to submit for publication. Dr. Lee is supported by the Singapore Ministry of Health’s National Medical Research Council under its Transition Award (Grant no.: NMRC/TA/002/2012 ).
Funding Information:
Dr. Takeuchi has received fellowship grants from the Japanese Society of Clinical Neuropsychopharmacology, Astellas Foundation for Research on Metabolic Disorders, and Centre for Addiction and Mental Health (CAMH) Foundation, and manuscript fees from Dainippon Sumitomo Pharma.
Publisher Copyright:
© 2015 Elsevier B.V. and ECNP.
PY - 2015/3/1
Y1 - 2015/3/1
N2 - The objective of this study was to evaluate the effectiveness and impact of once- versus twice-daily dosing of risperidone and olanzapine on clinical outcomes in patients with schizophrenia. Data from phase 1 of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia study were used. Patients with schizophrenia were randomly allocated to treatment with risperidone and olanzapine, and were also randomly assigned to once-daily (N=173 and 169, respectively) or twice-daily (N=168 and 167, respectively) dosing and followed for up to 18 months. Discontinuation rate and time to discontinuation were used as primary outcome measures to compare the two groups. The following outcome measures were also analyzed: efficacy, safety, medication adherence, adverse events, and concomitant psychotropic medications. No significant differences in discontinuation rates and time to discontinuation were observed between the once- and twice-daily dosing groups (P>0.05) in patients receiving risperidone or olanzapine. The once-daily dosing group demonstrated significantly lower mean daily doses of risperidone and olanzapine across phase 1, and lower rates of hospitalization for exacerbation of schizophrenia, sleepiness, and orthostatic faintness in patients receiving olanzapine (P<0.05) compared to the twice-daily dosing group. No significant differences were found in any other outcome measures between the two dosing groups. In conclusion, effectiveness and efficacy outcomes between once- and twice-daily dosing for risperidone and olanzapine were not significantly different. However, in view of the lower mean dose and better side effect profile, it is advisable to adhere to a once-daily dosing regimen, especially in the case of olanzapine.
AB - The objective of this study was to evaluate the effectiveness and impact of once- versus twice-daily dosing of risperidone and olanzapine on clinical outcomes in patients with schizophrenia. Data from phase 1 of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia study were used. Patients with schizophrenia were randomly allocated to treatment with risperidone and olanzapine, and were also randomly assigned to once-daily (N=173 and 169, respectively) or twice-daily (N=168 and 167, respectively) dosing and followed for up to 18 months. Discontinuation rate and time to discontinuation were used as primary outcome measures to compare the two groups. The following outcome measures were also analyzed: efficacy, safety, medication adherence, adverse events, and concomitant psychotropic medications. No significant differences in discontinuation rates and time to discontinuation were observed between the once- and twice-daily dosing groups (P>0.05) in patients receiving risperidone or olanzapine. The once-daily dosing group demonstrated significantly lower mean daily doses of risperidone and olanzapine across phase 1, and lower rates of hospitalization for exacerbation of schizophrenia, sleepiness, and orthostatic faintness in patients receiving olanzapine (P<0.05) compared to the twice-daily dosing group. No significant differences were found in any other outcome measures between the two dosing groups. In conclusion, effectiveness and efficacy outcomes between once- and twice-daily dosing for risperidone and olanzapine were not significantly different. However, in view of the lower mean dose and better side effect profile, it is advisable to adhere to a once-daily dosing regimen, especially in the case of olanzapine.
KW - Antipsychotics
KW - Dosing
KW - Olanzapine
KW - Risperidone
KW - Schizophrenia
UR - http://www.scopus.com/inward/record.url?scp=84925954000&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84925954000&partnerID=8YFLogxK
U2 - 10.1016/j.euroneuro.2014.12.008
DO - 10.1016/j.euroneuro.2014.12.008
M3 - Article
C2 - 25649680
AN - SCOPUS:84925954000
SN - 0924-977X
VL - 25
SP - 295
EP - 302
JO - European Neuropsychopharmacology
JF - European Neuropsychopharmacology
IS - 3
ER -
